Bayforest Capital Ltd Grows Stock Holdings in Apellis Pharmaceuticals, Inc. $APLS

Bayforest Capital Ltd boosted its holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) by 8.2% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 56,639 shares of the company’s stock after buying an additional 4,301 shares during the period. Bayforest Capital Ltd’s holdings in Apellis Pharmaceuticals were worth $980,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also bought and sold shares of APLS. Assetmark Inc. grew its stake in Apellis Pharmaceuticals by 3,938.7% in the 1st quarter. Assetmark Inc. now owns 1,252 shares of the company’s stock valued at $27,000 after buying an additional 1,221 shares in the last quarter. Parallel Advisors LLC boosted its holdings in Apellis Pharmaceuticals by 80.0% in the 2nd quarter. Parallel Advisors LLC now owns 1,924 shares of the company’s stock valued at $33,000 after purchasing an additional 855 shares during the period. GF Fund Management CO. LTD. boosted its holdings in Apellis Pharmaceuticals by 21.9% in the 1st quarter. GF Fund Management CO. LTD. now owns 3,185 shares of the company’s stock valued at $70,000 after purchasing an additional 573 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Apellis Pharmaceuticals by 15.6% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,855 shares of the company’s stock valued at $84,000 after purchasing an additional 655 shares during the period. Finally, Legacy Capital Group California Inc. boosted its holdings in Apellis Pharmaceuticals by 32.8% in the 1st quarter. Legacy Capital Group California Inc. now owns 9,554 shares of the company’s stock valued at $209,000 after purchasing an additional 2,359 shares during the period. 96.29% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Apellis Pharmaceuticals news, General Counsel David O. Watson sold 5,000 shares of the business’s stock in a transaction on Tuesday, September 16th. The shares were sold at an average price of $24.34, for a total value of $121,700.00. Following the completion of the sale, the general counsel directly owned 118,730 shares of the company’s stock, valued at $2,889,888.20. The trade was a 4.04% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Cedric Francois sold 49,963 shares of the business’s stock in a transaction on Thursday, August 28th. The stock was sold at an average price of $28.39, for a total transaction of $1,418,449.57. Following the completion of the sale, the chief executive officer directly owned 307,946 shares of the company’s stock, valued at $8,742,586.94. This represents a 13.96% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 291,554 shares of company stock valued at $7,843,356 over the last three months. Insiders own 6.80% of the company’s stock.

Analyst Ratings Changes

Several research analysts have commented on the stock. Royal Bank Of Canada raised their price target on shares of Apellis Pharmaceuticals from $17.00 to $19.00 and gave the company a “sector perform” rating in a report on Friday, August 1st. The Goldman Sachs Group downgraded shares of Apellis Pharmaceuticals from a “neutral” rating to a “sell” rating and cut their price target for the company from $26.00 to $18.00 in a report on Friday, September 26th. Bank of America raised their price target on shares of Apellis Pharmaceuticals from $23.00 to $24.00 and gave the company a “neutral” rating in a report on Wednesday, July 16th. Cantor Fitzgerald raised their price target on shares of Apellis Pharmaceuticals from $39.00 to $40.00 and gave the company an “overweight” rating in a report on Friday, August 1st. Finally, Wall Street Zen raised shares of Apellis Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, August 2nd. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, eight have given a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $33.29.

Apellis Pharmaceuticals Stock Performance

Apellis Pharmaceuticals stock opened at $24.14 on Tuesday. The company has a quick ratio of 3.16, a current ratio of 3.77 and a debt-to-equity ratio of 2.90. The company has a market capitalization of $3.05 billion, a PE ratio of -13.26 and a beta of 0.69. The firm has a fifty day simple moving average of $25.37 and a two-hundred day simple moving average of $21.11. Apellis Pharmaceuticals, Inc. has a twelve month low of $16.10 and a twelve month high of $35.72.

Apellis Pharmaceuticals (NASDAQ:APLS) last posted its quarterly earnings results on Thursday, July 31st. The company reported ($0.33) earnings per share for the quarter, topping the consensus estimate of ($0.44) by $0.11. The business had revenue of $171.39 million during the quarter, compared to the consensus estimate of $187.91 million. Apellis Pharmaceuticals had a negative net margin of 30.24% and a negative return on equity of 116.09%. The firm’s revenue for the quarter was down 10.6% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.30) earnings per share. Research analysts expect that Apellis Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).